AlbaTraDIS: Comparative analysis of large datasets from parallel transposon mutagenesis experiments.
Algorithms
Anti-Infective Agents
/ pharmacology
Computational Biology
DNA Transposable Elements
Drug Resistance, Bacterial
Escherichia coli
/ genetics
Gene Library
Genes, Essential
Genome, Bacterial
Genotype
High-Throughput Nucleotide Sequencing
Mutagenesis, Insertional
Mutation
Phenotype
Protein Biosynthesis
Software
Triclosan
/ pharmacology
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
09
05
2019
accepted:
23
05
2020
revised:
29
07
2020
pubmed:
18
7
2020
medline:
4
9
2020
entrez:
18
7
2020
Statut:
epublish
Résumé
Bacteria need to survive in a wide range of environments. Currently, there is an incomplete understanding of the genetic basis for mechanisms underpinning survival in stressful conditions, such as the presence of anti-microbials. Transposon directed insertion-site sequencing (TraDIS) is a powerful tool to identify genes and networks which are involved in survival and fitness under a given condition by simultaneously assaying the fitness of millions of mutants, thereby relating genotype to phenotype and contributing to an understanding of bacterial cell biology. A recent refinement of this approach allows the roles of essential genes in conditional stress survival to be inferred by altering their expression. These advancements combined with the rapidly falling costs of sequencing now allows comparisons between multiple experiments to identify commonalities in stress responses to different conditions. This capacity however poses a new challenge for analysis of multiple data sets in conjunction. To address this analysis need, we have developed 'AlbaTraDIS'; a software application for rapid large-scale comparative analysis of TraDIS experiments that predicts the impact of transposon insertions on nearby genes. AlbaTraDIS can identify genes which are up or down regulated, or inactivated, between multiple conditions, producing a filtered list of genes for further experimental validation as well as several accompanying data visualisations. We demonstrate the utility of our new approach by applying it to identify genes used by Escherichia coli to survive in a wide range of different concentrations of the biocide Triclosan. AlbaTraDIS identified all well characterised Triclosan resistance genes, including the primary target, fabI. A number of new loci were also implicated in Triclosan resistance and the predicted phenotypes for a selection of these were validated experimentally with results being consistent with predictions. AlbaTraDIS provides a simple and rapid method to analyse multiple transposon mutagenesis data sets allowing this technology to be used at large scale. To our knowledge this is the only tool currently available that can perform these tasks. AlbaTraDIS is written in Python 3 and is available under the open source licence GNU GPL 3 from https://github.com/quadram-institute-bioscience/albatradis.
Identifiants
pubmed: 32678849
doi: 10.1371/journal.pcbi.1007980
pii: PCOMPBIOL-D-19-00740
pmc: PMC7390408
doi:
Substances chimiques
Anti-Infective Agents
0
DNA Transposable Elements
0
Triclosan
4NM5039Y5X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007980Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/CCG1860/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R012504/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/F/000PR10349
Pays : United Kingdom
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: AKT is a named inventor on patents utilising transposon mutagenesis and has a financial interest in a company commercialising the technology. IGC has financial interests in companies commercialising transposon mutagenesis.
Références
Microb Genom. 2016 Sep 20;2(9):e000086
pubmed: 28785418
Bioinformatics. 2012 Feb 15;28(4):464-9
pubmed: 22199388
Bioinformatics. 2016 Apr 1;32(7):1109-11
pubmed: 26794317
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Mol Syst Biol. 2006;2:2006.0008
pubmed: 16738554
J Bacteriol. 2004 Dec;186(23):7926-35
pubmed: 15547264
J Antimicrob Chemother. 2004 May;53(5):693-5
pubmed: 15073159
J Antimicrob Chemother. 2009 Nov;64(5):973-85
pubmed: 19759044
mSphere. 2017 Nov 1;2(6):
pubmed: 29104937
PLoS One. 2015 Oct 26;10(10):e0140829
pubmed: 26501966
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1250-7
pubmed: 16978582
Clin Microbiol Rev. 2004 Oct;17(4):863-93, table of contents
pubmed: 15489352
Cell Host Microbe. 2009 Sep 17;6(3):279-89
pubmed: 19748469
Microb Genom. 2019 Feb;5(2):
pubmed: 30720421
Genome Announc. 2014 Oct 16;2(5):
pubmed: 25323716
mBio. 2018 Jul 24;9(4):
pubmed: 30042196
Genome Res. 2009 Dec;19(12):2308-16
pubmed: 19826075
J Appl Microbiol. 2002;92 Suppl:55S-64S
pubmed: 12000613
Sci Rep. 2017 Jul 17;7(1):5648
pubmed: 28717159
mBio. 2015 Feb 24;6(2):e02383
pubmed: 25714712
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Genetica. 1998;102-103(1-6):349-58
pubmed: 9720287
BMC Genomics. 2019 Jan 8;20(1):20
pubmed: 30621582
Nat Methods. 2018 Jul;15(7):475-476
pubmed: 29967506
J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):300-305
pubmed: 29109626
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16422-7
pubmed: 19805314
Nat Methods. 2009 Oct;6(10):767-72
pubmed: 19767758